12 West Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

12 West Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-263,000	Closed	-$30.3M	–	19
2019 Q4	$30.3M	Hold	263,000	–	–	1.91%	10
2019 Q3	$21.1M	Hold	263,000	–	–	1.36%	12
2019 Q2	$19.1M	Hold	263,000	–	–	1.44%	12
2019 Q1	$24.6M	Hold	263,000	–	–	2.01%	10
2018 Q4	$19.2M	Buy	263,000 +37,500	+17%	+$2.88M	1.97%	12
2018 Q3	$19.7M	Hold	225,500	–	–	1.45%	15
2018 Q2	$22.2M	Buy	+225,500	New	+$22.4M	1.83%	13

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

12 West Capital Management's ALNY Position: Q1 2021 in Review

12 West Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2021, closing a stake of 735,000 shares — an estimated $95.5M sold.

12 West Capital Management first reported a position in ALNY in Q3 2014 and held it in 26 quarters. The position peaked at $109M in Q2 2020. 391 funds tracked by Wall St. Rank hold ALNY as of Q1 2021.

12 West Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
12 West Capital Management sold 735,000 Alnylam Pharmaceuticals shares in Q1 2021, an estimated $95.5M.
12 West Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2014 and held it in 26 quarters.
12 West Capital Management's Alnylam Pharmaceuticals position peaked at $109M in Q2 2020.
391 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2021.

Based on 12 West Capital Management's 13F filing for Q1 2021, filed 17 May 2021.